Navigation Links
Enzyme may aid hold back disease

According to a new research it is found that an enzyme that rectifies mutations in genes could be a key factor in reducing a person's susceptibility to diseases such as hemophilia, cancer and cystic fibrosis. //Researchers from Cardiff University in Wales and the University of Edinburgh in Scotland have found the MBD4 enzyme could protect people from gene mutations that can lead to diseases.

Different combinations of genes are expressed in different cells. For example, a different combination of genes is expressed in heart cells as compared to liver cells. Researchers say mutations in these genes can lead to serious diseases, such as cancer. They say, although factors such as cigarette smoke and dietary habits may trigger genetic mutations, a lot of gene damage is caused simply by the natural chemistry that goes on in the human body. When a mutation occurs, the genes stop doing their jobs powerfully.

Researchers say one in three genetic changes or mutations that causes disease in people can be attributed to methyl-groups. Methyl-groups work to shut down genes, but in doing so significantly increase the risk of genetic mutation. Researchers have found the MBD4 enzyme attempts to repair the damage caused by methyl-groups before they cause harm.

Alan Clarke, a researcher from Cardiff University, felt that it is very likely the MBD4 is a key defense against self-inflicted gene damage in humans.In this study of lab animals, Professor Clarke and fellow researchers found mice lacking the MBD4 enzyme are up to three times more likely to have genetic mutations. Thus the study concludes that these findings suggest that human MBD4 plays an equally significant role in reducing inherited disease and cancer.


'"/>




Page: 1

Related medicine news :

1. Enzyme may be target for obesity drugs
2. Researchers trick Alzheimers Enzyme
3. Enzyme stimulates growth of adult stem cells
4. Enzyme help destroy cancer cell
5. Enzyme Associated with Memory
6. Enzyme Associated With Memory
7. Brain Enzyme Found To Regulate Weight
8. New Enzyme Identified For Arthritis
9. Enzyme for treatment of arthritis
10. An Enzyme That Turns a One –time Experience into a long-time Memor
11. Enzyme Responsible For Congenital Blindness
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... Yardley, PA (PRWEB) , ... March 23, 2017 ... ... received Patient Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s ... programs. , Accredited status is granted to organizations that have excellent programs ...
(Date:3/23/2017)... ... , ... The TouchPoint Solution, home of Buzzies *, is boosting the ... , “Buzzies change the way we interact with stress and live our day-to-day lives,” ... date in December 2016, The TouchPoint Solution has sold more than $750,000 in product ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
(Date:3/23/2017)... 23, 2017  Galmed Pharmaceuticals Ltd. (Nasdaq: ... clinical-stage biopharmaceutical company focused on the development of ... nonalcoholic steatohepatitis, or NASH, and other liver diseases, ... twelve months ended December 31, 2016, and announced new ... demonstrating Aramchol™,s potential direct effect on liver fibrosis. ...
(Date:3/23/2017)... 23, 2017 ReNeuron reported in December ... in chronic stroke patients, despite not meeting the three-month time ... the Action Research Arm Test (ARAT). As a result, the ... controlled clinical study in 2017. Beyond CTX, we expect safety ... 2017 and Phase I data from its critical limb ischaemia ...
Breaking Medicine Technology: